In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Encore Medical Goes Private

Executive Summary

Despite significant growth over the past several years, Encore Medical found it difficult to win over investors. So it has turned to private equity firm Blackstone Group to take it private, hoping that greater financial freedom will enable it to continue its aggressive growth.

You may also be interested in...



Acquisitions in 2007: Medical Device Companies Regroup

Looking back on 2007 through the lens of acquisition activity reveals a lot about the current dynamics in the medtech industry. According to Windhover's Strategic Transactions Database, many of the 80 medical devices companies that were acquired last year came from the perennially hot orthopedics and cardiovascular markets. But in 2007, buyers found their targets in clinical areas that are starting to heat up: patient monitoring, in vitro diagnostics, minimally invasive surgery, and women's health. The acquirers themselves were a mixed bag--for a change, traditional buyers didn't make up the largest share. In fact, those billion dollar plus companies were as likely to divest as to acquire in 2007.

Acquisitions in 2007: Medical Device Companies Regroup

Looking back on 2007 through the lens of acquisition activity reveals a lot about the current dynamics in the medtech industry. According to Windhover's Strategic Transactions Database, many of the 80 medical devices companies that were acquired last year came from the perennially hot orthopedics and cardiovascular markets. But in 2007, buyers found their targets in clinical areas that are starting to heat up: patient monitoring, in vitro diagnostics, minimally invasive surgery, and women's health. The acquirers themselves were a mixed bag--for a change, traditional buyers didn't make up the largest share. In fact, those billion dollar plus companies were as likely to divest as to acquire in 2007.

A White Knight for Bausch & Lomb

Bausch & Lomb was slogging forward after a difficult year-the company had been embroiled in a lengthy accounting investigation involving some of its foreign subsidiaries since the end of 2005 and in early 2006 it was compelled to recall its most profitable product-. In mid-May 2007 Bausch & Lomb was wrestling with a 3% decrease in annual sales, 344 product liability lawsuits, and an overhanging intellectual property case that could affect its fastest growing contact lens line, when up galloped white knight private equity firm Warburg Pincus, with a $4.5 billion offer to take the ophthalmic company private.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel